20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Use of medicines recommended for secondary prevention of acute coronary syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          OBJECTIVE

          : To analyze if the demographic and socioeconomic variables, as well as percutaneous coronary intervention are associated with the use of medicines for secondary prevention of acute coronary syndrome.

          METHODS

          : In this cohort study, we included 138 patients with acute coronary syndrome, aged 30 years or more and of both sexes. The data were collected at the time of hospital discharge, and after six and twelve months. The outcome of the study was the simultaneous use of medicines recommended for secondary prevention of acute coronary syndrome: platelet antiaggregant, beta-blockers, statins and angiotensin-converting-enzyme inhibitor or angiotensin receptor blocker. The independent variables were: sex, age, education in years of attending, monthly income in tertiles and percutaneous coronary intervention. We described the prevalence of use of each group of medicines with their 95% confidence intervals, as well as the simultaneous use of the four medicines, in all analyzed periods. In the crude analysis, we verified the outcome with the independent variables for each period through the Chi-square test. The adjusted analysis was carried out using Poisson Regression.

          RESULTS

          : More than a third of patients (36.2%; 95%CI 28.2;44.3) had the four medicines prescribed at the same time, at the moment of discharge. We did not observe any differences in the prevalence of use in comparison with the two follow-up periods. The most prescribed class of medicines during discharge was platelet antiaggregant (91.3%). In the crude analysis, the demographic and socioeconomic variables were not associated to the outcome in any of the three periods.

          CONCLUSIONS

          : The prevalence of simultaneous use of medicines at discharge and in the follow-ups pointed to the under-utilization of this therapy in clinical practice. Intervention strategies are needed to improve the quality of care given to patients that extend beyond the hospital discharge, a critical point of transition in care.

          Related collections

          Most cited references71

          • Record: found
          • Abstract: not found
          • Article: not found

          2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Adherence to long-term therapies: evidence for action.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

              Despite the use of aspirin, there is still a risk of ischaemic events after percutaneous coronary intervention (PCI). We aimed to find out whether, in addition to aspirin, pretreatment with clopidogrel followed by long-term therapy after PCI is superior to a strategy of no pretreatment and short-term therapy for only 4 weeks after PCI. 2658 patients with non-ST-elevation acute coronary syndrome undergoing PCI in the CURE study had been randomly assigned double-blind treatment with clopidogrel (n=1313) or placebo (n=1345). Patients were pretreated with aspirin and study drug for a median of 6 days before PCI during the initial hospital admission, and for a median of 10 days overall. After PCI, most patients (>80%) in both groups received open-label thienopyridine for about 4 weeks, after which study drug was restarted for a mean of 8 months. The primary endpoint was a composite of cardiovascular death, myocardial infarction, or urgent target-vessel revascularisation within 30 days of PCI. The main analysis was by intention to treat. There were no drop-outs. 59 (4.5%) patients in the clopidogrel group had the primary endpoint, compared with 86 (6.4%) in the placebo group (relative risk 0.70 [95% CI 0.50-0.97], p=0.03). Long-term administration of clopidogrel after PCI was associated with a lower rate of cardiovascular death, myocardial infarction, or any revascularisation (p=0.03), and of cardiovascular death or myocardial infarction (p=0.047). Overall (including events before and after PCI) there was a 31% reduction cardiovascular death or myocardial infarction (p=0.002). There was less use of glycoprotein IIb/IIIa inhibitor in the clopidogrel group (p=0.001). At follow-up, there was no significant difference in major bleeding between the groups (p=0.64). In patients with acute coronary syndrome receiving aspirin, a strategy of clopidogrel pretreatment followed by long-term therapy is beneficial in reducing major cardiovascular events, compared with placebo.
                Bookmark

                Author and article information

                Journal
                Rev Saude Publica
                Rev Saude Publica
                rsp
                Revista de Saúde Pública
                Faculdade de Saúde Pública da Universidade de São Paulo
                0034-8910
                1518-8787
                16 December 2015
                2015
                : 49
                : 88
                Affiliations
                [I ] Programa de Pós-Graduação em Saúde Coletiva. Universidade do Vale do Rio dos Sinos. São Leopoldo, RS, Brasil
                [II ]Departamento de Enfermagem e Odontologia. Universidade de Santa Cruz do Sul. Santa Cruz do Sul, RS, Brasil
                [III ]Instituto de Medicina Vascular do Hospital Mãe de Deus. Porto Alegre, RS, Brasil
                [IV ]Departamento de Nutrição. Universidade Federal de Ciências da Saúde de Porto Alegre. Porto Alegre, RS, Brasil
                [I ] Programa de Pós-Graduação em Saúde Coletiva. Universidade do Vale do Rio dos Sinos. São Leopoldo, RS, Brasil
                [II ] Departamento de Enfermagem e Odontologia. Universidade de Santa Cruz do Sul. Santa Cruz do Sul, RS, Brasil
                [III ]Instituto de Medicina Vascular do Hospital Mãe de Deus. Porto Alegre, RS, Brasil
                [IV ]Departamento de Nutrição. Universidade Federal de Ciências da Saúde de Porto Alegre. Porto Alegre, RS, Brasil
                Author notes
                [Correspondence ]:Juvenal Soares Dias da Costa. Universidade do Vale do Rio dos Sinos Av. Unisinos, 950. 93022-000 São Leopoldo, RS, Brasil. E-mail: episoares@ 123456terra.com.br

                AUTHORS' CONTRIBUTIONS

                MAG, JSDC, ERFM, RH, VMVP and MTAO participated in the elaboration of the project. MAG, MFN and MAM collected the data. MAG, JSDC, MFN and MAM analyzed the data. MAG and JSDC drafted the article and reviewed the bibliography. ERFM, RH, VMVP and MTAO reviewed the final version of the paper.

                Based on the masters dissertation by Mari Ângela Gaedke, titled: “Uso de medicamentos recomendados na prevenção secundária da Síndrome Coronariana Aguda”, presented at Graduate Program in Collective Health, of the Universidade do Vale do Rio dos Sinos, in 2013.

                The authors declare no conflict of interest.

                [Correspondência ]: Juvenal Soares Dias da Costa. Universidade do Vale do Rio dos Sinos. Av. Unisinos, 950. 93022-000 São Leopoldo, RS, Brasil. E-mail: episoares@terra.com.br

                CONTRIBUIÇÃO DOS AUTORES

                MAG, JSDC, ERFM, RH, VMVP e MTAO participaram da elaboração do Projeto. MAG, MFN e MAM coletaram os dados. MAG, JSDC, MFN e MAM analisaram os dados. MAG e JSDC redigiram o artigo e revisaram a bibliografia. ERFM, RH, VMVP e MTAO revisaram a versão final do artigo.

                Baseado na dissertação de mestrado de Mari Ângela Gaedke, intitulada: “Uso de medicamentos recomendados na prevenção secundária da Síndrome Coronariana Aguda” , apresentada ao Programa de Pós-Graduação em Saúde Coletiva da Universidade do Vale do Rio dos Sinos, em 2013.

                Os autores declaram não haver conflito de interesses.

                Article
                S0034-8910.2015049005978
                10.1590/S0034-8910.2015049005978
                4687825
                07b8fd8b-4cbd-498f-a3f2-bf6ec54f7b96

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 8 November 2014
                : 13 March 2015
                Page count
                Figures: 0, Tables: 8, Equations: 0, References: 27, Pages: 1
                Funding
                Funded by: CNPq
                Award ID: 30195/2010-0
                Research supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq – Process 30195/2010-0).
                Categories
                Original Articles

                acute coronary syndrome,secondary prevention,medication adherence,evidence-based medicine,cohort studies,síndrome coronariana aguda,prevenção secundária,adesão à medicação,medicina baseada em evidências,estudos de coortes

                Comments

                Comment on this article